Study type: Human research · Status: Verified against declared source
Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin.
PubMed · 2010
Study scale: Methods: Comparative analysis: Cerebrolysin treated (10 ml x 2/ day, i.v.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Background: Discovery of neurotrophic factors–emblematic: the nerve growth factor (NGF)–resulted in better approaching central nervous system (CNS) lesions.
Methods
Methods: Comparative analysis: Cerebrolysin treated (10 ml x 2/ day, i.v.
Scale or participants
Methods: Comparative analysis: Cerebrolysin treated (10 ml x 2/ day, i.v.
Key findings
Background: Discovery of neurotrophic factors–emblematic: the nerve growth factor (NGF)–resulted in better approaching central nervous system (CNS) lesions.
Limitations and uncertainty
Conclusion: Cerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, especially the recovery of some critical, for standing and walking, parameters.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.